Eligibility criteria for searches of RCTs in patients with IBD or uveitis treated with pharmaceutical drugs recognized as treatments for PsA.
| Factor | Inclusion Criteria | Exclusion Criteria |
|---|---|---|
| Study design | RCTs of any design (individual or cluster randomization, step-wedge design). Secondary, post hoc, and subgroup analyses of individual RCTs. Extension studies of RCTs. | Secondary evidence (ie, systematic reviews, guidelines/recommendations, evidence-based synopses). Quantitative primary studies that are not RCTs (eg, nonrandomized controlled studies, before-and-after studies, cohort studies, case studies, case series). Qualitative studies. Conference abstracts. Editorials, commentaries, trial protocols, letters, etc. |
| Participants and conditions of interest | Adult populations (age ≥ 18 yrs; if mixed ages, include if results for adults are reported separately or if most participants are adults). Diagnosis of IBD (UC, CD, subclinical colitis) or uveitis. | Pediatric only focus (< 18 yrs). |
| Interventions or exposures | Any DMARD, targeted synthetic or biologic drug or combination used in the treatment of PsA (oral, injection, IV). | Nonpharmacological interventions. NSAIDs only. Steroids only. |
| Comparisons or control groups | Any comparator (active, sham, PBO). | NA. |
| Outcomes of interest | Symptoms and signs including outcomes relating to disease activity and impact. Disease progression. Safety outcomes (AEs, side effects). Any length of follow-up will be considered. | |
| Setting | Any. |
AE: adverse event; CD: Crohn disease; DMARD: disease-modifying antirheumatic drug; IBD: inflammatory bowel disease; IV: intravenous; NA: not applicable; NSAID: nonsteroidal antiinflammatory drug; PBO: placebo; PsA: psoriatic arthritis; RCT: randomized controlled trial; UC: ulcerative colitis.